Sylvie B.
- Country
- France
- Department
- Pédiatrie
Research Overview
- Randomized, Double-Blind, Placebo-Controlled Trial of Galcanezumab in Adolescents Aged 12-17 with Chronic Migraine: REBUILD-2 Study
- Analgesic effectiveness of capsaicin 8% cutaneous patch for the treatment of chronic postsurgical or post-traumatic neuropathic pain: a randomized placebo controlled study in children aged 12 to 17-y
Data & Insights
Has run more than one trial at 3 of 27 partner sites.
Specializations
Pediatric Pain Management
The investigator specializes in treating chronic pain conditions in adolescent populations, with particular emphasis on innovative therapeutic approaches for patients aged 12-17 years.
- Chronic Migraine Prevention
- Post-surgical Pain Management
- Post-traumatic Neuropathic Pain
A key focus lies in evaluating advanced treatment options for neuropathic pain syndromes and migraine prevention in young patients.
Neurological Disorders
The investigator concentrates on adolescent neurology, particularly exploring therapeutic solutions for chronic neurological conditions affecting quality of life in young patients.
- Chronic Migraine Management
- Neuropathic Pain Assessment
- Pain Symptom Evaluation
Their work encompasses the evaluation of novel therapeutic approaches for managing complex neurological pain conditions in pediatric populations.
Therapeutic Applications
The investigator explores diverse treatment modalities including cutaneous applications and specialized medications for chronic pain conditions in adolescents.
- Analgesic Effectiveness Studies
- Pain Prevention Strategies
- Symptom Management Protocols
Their therapeutic focus includes investigating preventive treatments and pain management solutions specifically designed for younger patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.